BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
Revenue Growth %: +32.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $116.6 million versus the consensus estimate of $119.24 million.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
